Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08TEJ
|
||||
Former ID |
DIB007590
|
||||
Drug Name |
CB-03-01
|
||||
Synonyms |
Cortexolone 17alpha-propionate; Androgen receptor antagonist (alopecia, acne, seborrhea, hirsuitism), Cosmo
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Acne vulgaris [ICD9: 706.1; ICD10:L70.0] | Phase 2 | [1] | ||
Company |
Cosmo Pharmaceuticals SpA
|
||||
Structure |
Download2D MOL |
||||
Formula |
C24H34O5
|
||||
Canonical SMILES |
[C@]1([C@@]2([C@@H](CC1)[C@H]1[C@H](CC2)[C@@]2(C(=CC(=O<br />)CC2)CC1)C)C)(OC(=O)CC)C(=O)CO
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Androgen receptor | Target Info | Antagonist | [2] | |
KEGG Pathway | Oocyte meiosis | ||||
Pathways in cancer | |||||
Prostate cancer | |||||
NetPath Pathway | EGFR1 Signaling Pathway | ||||
AndrogenReceptor Signaling Pathway | |||||
FSH Signaling Pathway | |||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Coregulation of Androgen receptor activity | |||||
Regulation of Androgen receptor activity | |||||
Nongenotropic Androgen signaling | |||||
Regulation of nuclear beta catenin signaling and target gene transcription | |||||
FOXA1 transcription factor network | |||||
Notch-mediated HES/HEY network | |||||
Reactome | Nuclear Receptor transcription pathway | ||||
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Integrated Pancreatic Cancer Pathway | |||||
Prostate Cancer | |||||
Integrated Breast Cancer Pathway | |||||
Nuclear Receptors | |||||
Androgen receptor signaling pathway | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026561) | ||||
REF 2 | Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.